SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending amid discussions around market downturns, potential support levels, and the influence of macroeconomic factors. Community members are debating whether this is a buying opportunity or the start of a deeper correction, while also considering the impact of potential government actions and large liquidations. Some traders are pointing to technical indicators and historical patterns to predict future price movements.

Pupu is a community-driven meme project centered around the character “Pupu the Frog,” who represents lighthearted fun and adventure within the crypto space. The project aims to build a digital ecosystem where holders can engage with the narrative of Pupu through memes, social interactions, and community activities. At its core, the project highlights creativity, entertainment, and community participation as primary utilities, while maintaining a transparent and decentralized structure that evolves through user engagement.

Pupu

$PUPU.X is trending as community members discuss its potential to be the next PEPE, with many highlighting its availability on the Solana blockchain via Phantom Wallet. The coin is experiencing increased attention and bullish sentiment, with some suggesting it's gearing up for a significant breakout.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

The stock is trending as investors digest a newly announced AI hosting agreement with Fluidstack, backed by Google, and an $800 million convertible note offering. While some view the deal as a major win with long-term potential in the AI data center space, others are concerned about potential dilution from the convertible notes. Community discussions revolve around the details of the deal, potential for future growth, and whether the recent price drop is a buying opportunity or a sign of further declines.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is trending due to increased community interest following a recent mention on Jim Cramer's Mad Money, highlighting potential FDA approval of their epinephrine sublingual film, Anaphylm. The community is actively discussing the positive implications of the Cramer mention, the potential for a squeeze, and the possible competitive advantages over existing treatments like EpiPen and Neffy. Some caution against the Cramer effect while others celebrate the increased awareness for AQST.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Fueled by positive clinical trial results for its oral acromegaly treatment, CRNX is trending as traders discuss the potential for a short squeeze given high short interest and substantial institutional ownership. The community is closely watching for the offering to close and debating its impact on the stock's price action, with some anticipating a continued rise while others foresee a pullback. Bullish sentiment is supported by analysts' optimistic revenue projections, while bears point to the company's financials and insider selling.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as discussions revolve around rare earth elements and potential price floors being considered by G7 nations to counter China's dominance in the sector. Community members are weighing the potential impacts of government stakes and contracts, drawing comparisons to Lithium Americas, while also speculating on future price targets. Investors are closely monitoring technical indicators and upcoming catalysts, such as earnings and processing capacity increases.

$JINGLE  is a meme community on Solana, The project was fair-launched on Pump.fun, This is a purely community-driven project.  $JINGLE a community powered token celebrating global holidays!  With a dedicated team and a vibrant community, $JINGLE Token aims to bring joy and prosperity to holders while embodying the spirit of the internet's favorite amphibian. Jump on board and let's make waves in the crypto pond together!

Jingle

JINGLE.X is trending as community members are actively discussing potential gains and encouraging others to buy, with some mentioning a possible pump. Several are drawing comparisons to other meme coins and touting it as the next opportunity for significant returns. The conversation also includes promotion of related Solana-based tokens, creating a broader buzz within that ecosystem.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas Corp ($LAC) is trending due to speculation around a potential equity stake from the US government, linked to a loan renegotiation for the Thacker Pass lithium project. The community is buzzing about the potential for a short squeeze and comparing it to past government investments in companies like MP Materials. Some traders are setting price targets, while others remain cautious, citing concerns about dilution and the company's financials.

Concentrix Corp. engages in the provision of customer experience solutions and technology. The company was founded in 1973 and is headquartered in Newark, CA.

Concentrix Corp.

Concentrix Corporation

Concentrix (CNXC) is trending following an earnings report that included lowered guidance, which has sparked debate among investors regarding a potential overdone sell-off. Community members are weighing whether the stock will rebound or test lower support levels, while also noting a significant short interest that could lead to a squeeze. Despite the negative reaction, some are pointing to the company's low PE ratio as a reason for optimism.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE.X is trending as its community rallies behind the coin, expressing bullish sentiment and encouraging others to join. Many allude to support from notable investors and highlight the strength of the community-driven movement. The coin is associated with the popular Rage Guy meme, potentially contributing to its appeal within the crypto space.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Sionna Therapeutics, Inc. (SION) Rating Upgrade to Buy

Sionna Therapeutics, Inc. (SION) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts See a 66.51% Upside in Sionna Therapeutics, Inc. (SION): Can the Stock Really Move This High?

The mean of analysts' price targets for Sionna Therapeutics, Inc. (SION) points to a 66.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The short squeeze in Sionna Therapeutics shares that followed a 45% post-earnings rally has cooled, with shorts rising to 23.7% of free float from 21.5% as the stock slipped about 10% last week.The biopharmaceutical firm, which is developing novel therapies for cystic fibrosis, drew conflicting sell-side views, according to The Fly, which compiled data on the short squeeze from Ortex.&nbsp;Raymond James initiated coverage with a ‘Strong Buy’ rating and $45 price target, saying Sionna has the best chance in the industry at breaking Vertex Pharmaceuticals’ stronghold in cystic fibrosis. RBC Capital Markets began at ‘Sector Perform’ with a $22 target, noting that existing treatments set a high bar and that Sionna’s next key data readouts in mid-2026 may not meaningfully de-risk the program.Sionna is advancing two first-in-class NBD1 stabilizers, SION-719 and SION-451. Both produced positive Phase 1 safety and pharmacokinetic results in June, exceeding target exposure levels.&nbsp;The company plans to start a Phase 2a proof-of-concept trial of SION-719 as an add-on to standard of care in the second half of 2025 and a Phase 1 trial of SION-451 in two proprietary dual combinations over the same period, with topline data from both expected in mid-2026.&nbsp;Preclinical findings presented in June showed that the stabilizers, when combined with complementary modulators, enabled full correction of F508del-CFTR in models.In second-quarter results released last month, Sionna reported a net loss of $18.1 million, or a loss of $0.41 per share, compared with a loss of $2.71 a year earlier, on higher R&amp;D expenses of $15.4 million.&nbsp;General and administrative expenses rose to $6.5 million from $3.1 million. The company ended June with $337.3 million in cash and equivalents, which it stated&nbsp;should be sufficient to fund operations&nbsp;through 2028.On Stocktwits, retail sentiment for Sionna was ‘bearish’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/SION">Sionna’s stock</a> has declined 4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sionna’s stock (SION) has declined 4% so far in 2025. (Photo credit: Getty Images)

Sionna Short Squeeze Fades As Raymond James Backs Cystic Fibrosis Breakthrough, RBC Warns Treatments Set High Bar

The biopharmaceutical firm’s shorts climbed to 23.7% of free float last week as the stock slipped 10%.

Equity

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a robust pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.

Sionna Therapeutics Inc.

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

SION
Sionna Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SION News

SION Sionna Therapeutics Inc